Research on issues in the protection of clinical trial human subjects in China: a Delphi study

This study aims to identify current deficiencies in the protection of human subjects participating in clinical trials in China and propose strategies for safeguarding their rights. We conducted a comprehensive literature review on the protection of human subjects in clinical trials and gathered insights from experts and scholars among stakeholders. The Delphi expert consultation method was used to analyze and summarize the shortcomings in China’s regulatory framework for human subject protection and to develop strategies for improvement. Two rounds of surveys were conducted with experts from research institutions, ethics committees, regulatory agencies, sponsors, and Site Management Organizations (SMOs). The top three issues and proposed solutions were discussed and addressed based on expert consensus. A total of 30 articles were reviewed, leading to the identification of 46 distinct issues, which were categorized into three groups: compensation, privacy, and informed consent. Sixteen respondents completed both rounds of the survey, which included 56 questions (10 new questions were proposed in the first round). Compensation-related issues included the absence of a comprehensive “mandatory insurance system,” incomplete insurance systems and compensation procedures, and the lack of clear differentiation between liability for clinical trial infringements and medical harm. Privacy concerns involved inadequate regulations, privacy risks associated with third-party recruitment, and data entry by clinical research coordinators. Problems related to informed consent were primarily due to inadequate awareness and capacity among investigators, a lack of oversight by ethics committees, and the absence of legal standards for broad informed consent. By improving the details of compensation rights, privacy protection, and informed consent in regulations, all parties involved in clinical trials can be encouraged to more effectively protect the rights and interests of subjects.

Authors

Institutions

Publication Details

Journal
BMC Medical Ethics
Published
2025-11-14
DOI
https://doi.org/10.1186/s12910-025-01302-5
Citations
1
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
1.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Research on issues in the protection of clinical trial human subjects in China: a Delphi study

Jinghong Gao, Chunyan Ai, Xiaoyi Xu, Rong Yu et al.
1 citations
BMC Medical Ethics
Ethics in Clinical Research
1.88
article

Research on issues in the protection of clinical trial human subjects in China: a Delphi study

Jinghong Gao, Chunyan Ai, Xiaoyi Xu, Rong Yu, Lin Hong, Xiuqiao Yang, Yuwen Chen, Shuning Liu, Ping Wen, Zucong Cai
article en
1 citations

Abstract

This study aims to identify current deficiencies in the protection of human subjects participating in clinical trials in China and propose strategies for safeguarding their rights. We conducted a comprehensive literature review on the protection of human subjects in clinical trials and gathered insights from experts and scholars among stakeholders. The Delphi expert consultation method was used to analyze and summarize the shortcomings in China’s regulatory framework for human subject protection and to develop strategies for improvement. Two rounds of surveys were conducted with experts from research institutions, ethics committees, regulatory agencies, sponsors, and Site Management Organizations (SMOs). The top three issues and proposed solutions were discussed and addressed based on expert consensus. A total of 30 articles were reviewed, leading to the identification of 46 distinct issues, which were categorized into three groups: compensation, privacy, and informed consent. Sixteen respondents completed both rounds of the survey, which included 56 questions (10 new questions were proposed in the first round). Compensation-related issues included the absence of a comprehensive “mandatory insurance system,” incomplete insurance systems and compensation procedures, and the lack of clear differentiation between liability for clinical trial infringements and medical harm. Privacy concerns involved inadequate regulations, privacy risks associated with third-party recruitment, and data entry by clinical research coordinators. Problems related to informed consent were primarily due to inadequate awareness and capacity among investigators, a lack of oversight by ethics committees, and the absence of legal standards for broad informed consent. By improving the details of compensation rights, privacy protection, and informed consent in regulations, all parties involved in clinical trials can be encouraged to more effectively protect the rights and interests of subjects.

BMC Medical EthicsVol. 26(1)
Shenyang Pharmaceutical University (CN), Shenzhen Maternity and Child Healthcare Hospital (CN)
Shenyang Pharmaceutical University
Openalex Percentile: Top 11%
Ethics in Clinical Research
1.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.